a) Exenatide b) Liraglutide c) Dulaglutide d) Semaglutide Answer: d) Semaglutide Cardiovascular benefits of GLP-1 agonists are most evident in: a) Type 1 diabetes b) Type 2 diabetes with CV risk c) Healthy adults d) Children Answer: b) Type 2 diabetes with CV risk GLP-1 receptor agonists delay: a) Insulin action b) Glucose absorption c) Gastric emptying d) Renal excretion Answer: c) Gastric emptying Pancreatitis is a: a) Common effect b) Contraindication c) Rare adverse effect d) Desired action Answer: c) Rare adverse effect Main site of GLP-1 receptor action for appetite regulation is: a) Pancreas b) Liver c) Hypothalamus d) Kidney Answer: c) Hypothalamus Liraglutide is FDA-approved for: a) Anemia b) Depression c) Weight loss d) Osteoporosis Answer: c) Weight loss FAQs 1
McIntyre RS, Powell AM, Kaidanovich-Beilin O, Soczynska JK, Alsuwaidan M, Woldeyohannes HO, Kim AS, Gallaugher LA (2013) The neuroprotective effects of GLP-1: possible treatments for cognitive deficits in individuals with mood disorders
Ganner A, Pfeiffer Z-C, Wingendorf L, Kreis S, Klein M, Walz G, et al
Pat your skin until it's slightly damp--not bone-dry--since a bit of moisture helps water-based serums spread evenly
Consent for publication No consent is needed, as this manuscript contains no personal data
